SBIR CONCEPT AWARD-NANOSPONGE LINKED DCLK1 INHIBITORS FOR THE TARGETED TREATMENT OF CHOLANGIOCARCINOMA

SBIR 概念奖-纳米海绵连接的 DCLK1 抑制剂用于胆管癌的靶向治疗

基本信息

  • 批准号:
    10975720
  • 负责人:
  • 金额:
    $ 35.34万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-02-28 至 2024-02-27
  • 项目状态:
    已结题

项目摘要

DCLK1 LLC is a startup pharmaceutical company focused on developing novel "nano-sponge" linked small molecule DCLK1 inhibitors for treating cholangiocarcinoma (CCA), a rare and aggressive malignancy of the bile ducts that presents at a late stage with poor outcomes. The incidence of CCA increases with age with a 5-Year survival of CCA is 13% (median survival 7 months). Incidence of CCA is increasing and DCLK1 LLC estimates more than 10,865 US incidence in 2022. Cytotoxic chemotherapy is currently the standard of care for CCA patients treated perioperatively. DCLK1 LLC is collaborating with KUMC researchers on a novel treatment strategy for CCA. Doublecortin Calmodulin-like Kinase 1 (DCLK1) is a serine-threonine kinase which represents a novel therapeutic target in oncology. Our team has shown that both knockdown of DCLK1 expression and small molecule DCLK1 inhibitors suppress xenograft tumor growth in mice. DCLK1 LLC's strategy to maximize the efficacy and safety of DCLK1 inhibitors is to deliver these potent molecules to the site of the tumors in the biliary tract using a rationally designed peptide nanosponge technology. Taken together these two unique technologies offer the possibility of administering breakthrough treatment directly to the liver and changing the treatment paradigm for CCA patients.
DCLK 1 LLC是一家初创制药公司,专注于开发新型“纳米海绵”, 小分子DCLK 1抑制剂用于治疗胆管癌(CCA),一种罕见的侵袭性 胆管恶性肿瘤,出现在晚期,预后差。CCA的发病率 随着年龄的增长,CCA的5年生存率为13%(中位生存期为7个月)。发生率 CCA正在增加,DCLK 1 LLC估计到2022年美国的发病率将超过10,865。细胞毒性 化疗目前是CCA患者围手术期治疗的标准护理。 DCLK 1 LLC正在与KUMC研究人员合作,研究一种新的CCA治疗策略。 Doublecortin 钙调素样激酶1(DCLK 1)是一种丝氨酸-苏氨酸激酶, 肿瘤学的目标。我们的团队已经证明,DCLK 1表达的敲低和小分子 DCLK 1抑制剂抑制小鼠异种移植肿瘤生长。 DCLK 1 LLC最大限度地提高DCLK 1抑制剂的疗效和安全性的策略是提供这些 使用合理设计的肽, 纳米海绵技术这两种独特的技术结合在一起, 直接对肝脏进行突破性治疗, CCA患者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

THAIS SIELECKI其他文献

THAIS SIELECKI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Developing Teaching Tools to Promote Transfer of Core Concept Knowledge Across Biological Scales and Sub-disciplines.
开发教学工具以促进跨生物尺度和子学科的核心概念知识的转移。
  • 批准号:
    2336776
  • 财政年份:
    2024
  • 资助金额:
    $ 35.34万
  • 项目类别:
    Standard Grant
Individualism and Intentionality: A Research on the Genealogy and Political Ramifications of the Market Concept in Neoliberal Thought
个人主义与意向性:新自由主义思想中市场概念的谱系及其政治影响研究
  • 批准号:
    24K03432
  • 财政年份:
    2024
  • 资助金额:
    $ 35.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Concept Driftの網羅探索
概念漂移综合搜索
  • 批准号:
    24K15082
  • 财政年份:
    2024
  • 资助金额:
    $ 35.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A Space Warehouse Concept and Ecosystem to Energize European OSAM (STARFAB)
为欧洲 OSAM 注入活力的太空仓库概念和生态系统 (STARFAB)
  • 批准号:
    10092765
  • 财政年份:
    2024
  • 资助金额:
    $ 35.34万
  • 项目类别:
    EU-Funded
Repurposing Sodium Cromoglycate For Lymphangioleiomyomatosis (LAM): An Open Label, Proof Of Concept And Feasibility Study
重新利用色甘酸钠治疗淋巴管平滑肌瘤病 (LAM):开放标签、概念验证和可行性研究
  • 批准号:
    MR/Y008618/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.34万
  • 项目类别:
    Research Grant
Use and Concept in Neural Machine Translation and Cross-Linguistic Divergence
神经机器翻译和跨语言分歧中的使用和概念
  • 批准号:
    23K21872
  • 财政年份:
    2024
  • 资助金额:
    $ 35.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Proactive Ex Ante Digital Platform Regulations and the Concept of “Fairness”
积极主动的事前数字平台监管和“公平”理念
  • 批准号:
    24K16261
  • 财政年份:
    2024
  • 资助金额:
    $ 35.34万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Oncological Engineering - A new concept in the treatment of bone metastases
肿瘤工程——治疗骨转移的新概念
  • 批准号:
    EP/W007096/2
  • 财政年份:
    2024
  • 资助金额:
    $ 35.34万
  • 项目类别:
    Research Grant
Developing Teaching Tools to Promote Transfer of Core Concept Knowledge Across Biological Scales and Sub-disciplines.
开发教学工具以促进跨生物尺度和子学科的核心概念知识的转移。
  • 批准号:
    2336777
  • 财政年份:
    2024
  • 资助金额:
    $ 35.34万
  • 项目类别:
    Standard Grant
Developing Teaching Tools to Promote Transfer of Core Concept Knowledge Across Biological Scales and Sub-disciplines.
开发教学工具以促进跨生物尺度和子学科的核心概念知识的转移。
  • 批准号:
    2336778
  • 财政年份:
    2024
  • 资助金额:
    $ 35.34万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了